Comerica Bank Acquires 3,476 Shares of AngioDynamics, Inc. (ANGO)
Comerica Bank boosted its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 9.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,724 shares of the medical instruments supplier’s stock after acquiring an additional 3,476 shares during the quarter. Comerica Bank’s holdings in AngioDynamics were worth $910,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Financial Gravity Companies Inc. acquired a new stake in AngioDynamics in the fourth quarter valued at approximately $43,000. Quantamental Technologies LLC acquired a new stake in AngioDynamics in the fourth quarter valued at approximately $67,000. Advisor Group Inc. raised its holdings in AngioDynamics by 21.4% in the fourth quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 601 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in AngioDynamics by 28.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock valued at $107,000 after acquiring an additional 1,181 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in AngioDynamics in the fourth quarter valued at approximately $113,000. 98.46% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:ANGO opened at $18.78 on Tuesday. The company has a market capitalization of $699.29 million, a P/E ratio of 24.40 and a beta of 0.71. AngioDynamics, Inc. has a fifty-two week low of $18.11 and a fifty-two week high of $25.48. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.70 and a current ratio of 2.68.
Several brokerages recently weighed in on ANGO. BidaskClub cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a report on Wednesday, April 24th. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a report on Thursday, May 16th. TheStreet cut shares of AngioDynamics from a “b” rating to a “c+” rating in a report on Thursday, April 18th. Finally, ValuEngine cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Friday, April 19th. One analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $23.50.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2019/06/04/comerica-bank-acquires-3476-shares-of-angiodynamics-inc-ango.html.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Recommended Story: What is a good dividend yield?
Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.